Review anchor
Carbapenem-hydrolizing beta-lactamase SFC-1
SINGLE PROTEIN · Serratia fonticola
As of 2026-09-13
Evidence Snapshot
Carbapenem-hydrolizing beta-lactamase SFC-1
CHEMBL5042
SINGLE PROTEIN
Serratia fonticola
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Carbapenem-hydrolizing beta-lactamase SFC-1 as ChEMBL target CHEMBL5042, mapped to UniProt Q6JP75. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5042
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q6JP75
beta-lactamase
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Carbapenem-hydrolizing beta-lactamase SFC-1 matters
Carbapenem-hydrolizing beta-lactamase SFC-1 is reviewed as beta-lactamase (UniProt Q6JP75); the current evidence base includes 3 approved drugs, 13 compounds, and 3 assays, with lead potency reaching pChEMBL 5.2.
Protein context
beta-lactamase
beta-lactamase Sequence length is 309 aa.
Review this target as Carbapenem-hydrolizing beta-lactamase SFC-1, mapped to UniProt Q6JP75. ChEMBL maps the protein component as beta-lactamase. Sequence length is 309 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q6JP75
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 3 approved drugs, 13 compounds, and 3 assays for this target. The dominant activity type is IC50. CHEMBL404 is the current potency anchor at pChEMBL 5.2.
Use CHEMBL404 as the tractability anchor when discussing potency (pChEMBL 5.2).
Activity source · ChEMBL 36 via Core Engine
3 approved
pChEMBL 5.2
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Carbapenem-hydrolizing beta-lactamase SFC-1 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q6JP75, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
13
Total Compounds
3
Total Assays
3
Approved Drugs
IC50: 3.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL404
|
5.2 | IC50 | Approved |
|
|
No preferred name
CHEMBL403
|
4.6 | IC50 | Approved |
|
|
No preferred name
CHEMBL777
|
4.1 | IC50 | Approved |
Source Header